Acrivastine: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
(2 intermediate revisions by one other user not shown)
Line 1: Line 1:
{{drugbox |
{{Drugbox
| IUPAC_name       = (''E'')-3-{6-[(''E'')-1-(4-methylphenyl)-3-pyrrolidin-1-yl-<br>prop-1-enyl]pyridin-2-yl}prop-2-enoic acid
| Verifiedfields = changed
| image             =
| verifiedrevid = 477241254
| CAS_number        = 87848-99-5
| IUPAC_name = (''E'')-3-{6-[(''E'')-1-(4-methylphenyl)-3-pyrrolidin-1-yl-<br>prop-1-enyl]pyridin-2-yl}prop-2-enoic acid
| ATC_prefix        = R06
| image =Acrivastine.png
| ATC_suffix        = AX18
 
| PubChem          = 5284514
<!--Clinical data-->
| DrugBank          =  
| tradename =
| C = 22 | H = 24 | N = 2 | O = 2
| Drugs.com = {{drugs.com|international|acrivastine}}
| molecular_weight  = 348.438 g/mol
| MedlinePlus = a682619
| smiles            = CC1=CC=C(C=C1)C(=CCN2CCCC2)C3=CC=CC(=N3)C=CC(=O)O
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| bioavailability  =  
| pregnancy_US = B
| protein_bound    =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| metabolism        =
| legal_CA = <!--            / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL        / P      / POM / CD / Class A, B, C -->
| legal_US = Rx-only
| routes_of_administration = oral
 
<!--Pharmacokinetic data-->
| elimination_half-life = 1.5 hours
| elimination_half-life = 1.5 hours
| excretion         = [[Kidney|Renal]]
| excretion = [[Kidney|Renal]]
| pregnancy_AU      =  <!-- A / B1 / B2 / B3 / C / D / X -->
 
| pregnancy_US      = <!-- A / B            / C / D / X -->
<!--Identifiers-->
| pregnancy_category=
| CAS_number_Ref = {{cascite|changed|??}}
| legal_AU          = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| CAS_number = 87848-99-5
| legal_CA          =  <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| ATC_prefix = R06
| legal_UK          = <!-- GSL        / P      / POM / CD / Class A, B, C -->
| ATC_suffix = AX18
| legal_US          =  <!-- OTC                  / Rx-only  / Schedule I, II, III, IV, V -->
| PubChem = 5284514
| legal_status      =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| routes_of_administration =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4447574
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = A20F9XAI7W
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02760
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1224
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 83168
 
<!--Chemical data-->
| C=22 | H=24 | N=2 | O=2
| molecular_weight = 348.438 g/mol
| smiles = O=C(O)\C=C\c3nc(\C(=C\CN1CCCC1)c2ccc(cc2)C)ccc3
| InChI = 1/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+
| InChIKey = PWACSDKDOHSSQD-IUTFFREVBW
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = PWACSDKDOHSSQD-IUTFFREVSA-N
}}
}}
 
__Notoc__
{{SI}}
{{SI}}
{{CMG}}
==Overview==
'''Acrivastine''' is a medication used for the treatment of allergies and [[hay fever]]. It is a second-generation [[H1 antagonist|H1-receptor antagonist]] [[antihistamine]] (like its base molecule [[triprolidine]]) and works by blocking [[Histamine H1 receptor]]s.


This non-sedating{{verify source|date=November 2014}} antihistamine is sold under the brand name Benadryl Allergy Relief in the [[United Kingdom]] by [[McNeil Laboratories]], not to be confused with Benadryl Once a Day, which is [[cetirizine]] and is also sold by McNeil in the UK. It is available as an over-the-counter medication in the UK, also offered with pseudoephedrine under the Benadryl brand


==Overview==
In the U.S., acrivastine is the active ingredient in the Semprex brand. Semprex-D is also acrivastine-based, but contains a [[decongestant]], [[pseudoephedrine]]. Semprex-D is marketed in the U.S. by Actient Pharmaceuticals.<ref>[http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=7627 SEMPREX-D - acrivastine and pseudoephedrine hydrochloride capsule] U.S. [[National Library of Medicine]], National Institutes of Health, May 2008</ref>
'''Acrivastine''' is a medication used for the treatment of allergies and hay fever. It is a second-generation H1-receptor antagonist [[antihistamine]] and works by blocking H1 histamine receptors.  
 
It is sold under the brand name ''Benadryl Allergy Relief'' in the U.K. by [[Pfizer]], not to be confused with ''Benadryl Once a Day'', which is [[cetirizine]] and is also sold by Pfizer in the U.K.
This drug is currently not available as a generic in the U.K. <ref>[http://forums.moneysavingexpert.com/showthread.html?t=441494 Cheapest hayfever remedies 2007], Money Saving expert, May 15th,2007</ref>


In the [[U.S.]], ''acrivastine'' is the active ingrediant in the ''Semprex'' brand. [[Semprex-D]] is also ''acrivastine'' based, but also contains a decongestant.
==Comparisons with other popular antihistamines==
Unlike [[cetirizine]] or [[loratadine]], the standard dosage of which is one tablet every day, a single acrivastine tablet may be taken up to three times a day.<ref>{{cite web |url=http://www.medicines.org.uk/EMC/pdfviewer.aspx?isAttachment=true&documentid=21852 |title=Benadryl Allergy Relief |work=electronic Medicines Compendium (eMC) |year=2014 |accessdate=4 July 2014}}</ref> Not to be taken by over 65's, pregnant women or people with compromised liver or kidney function.


===Pill Images===
==Pill Images==
{{TempDrugImages}}
{{TempDrugImages}}
{{PillImage|fileName=SEMPREX_NDC_522440404.jpg|drugName=SEMPREX|NDC=522440404|drugAuthor=Actient Pharmaceuticals, LLC|ingredients=ACRIVASTINE[ACRIVASTINE];PSEUDOEPHEDRINE HYDROCHLORIDE[PSEUDOEPHEDRINE]|pillImprint=404;SEMPREX;D|dosageValue=8|dosageUnit=mg|pillColor=Green|pillShape=Capsule|pillSize=16|pillScore=1}}
{{PillImage|fileName=SEMPREX_NDC_522440404.jpg|drugName=SEMPREX|NDC=522440404|drugAuthor=Actient Pharmaceuticals, LLC|ingredients=ACRIVASTINE[ACRIVASTINE];PSEUDOEPHEDRINE HYDROCHLORIDE[PSEUDOEPHEDRINE]|pillImprint=404;SEMPREX;D|dosageValue=8|dosageUnit=mg|pillColor=Green|pillShape=Capsule|pillSize=16|pillScore=1}}
{{PillImage|fileName=Semprex-D_NDC_530140404.jpg|drugName=Semprex-D|NDC=530140404|drugAuthor=UCB, Inc.|ingredients=acrivastine[acrivastine];pseudoephedrine hydrochloride[pseudoephedrine]|pillImprint=404;SEMPREX-D|dosageValue=8|dosageUnit=mg|pillColor=Green;White|pillShape=Capsule|pillSize=16|pillScore=1}}
{{PillImage|fileName=Semprex-D_NDC_530140404.jpg|drugName=Semprex-D|NDC=530140404|drugAuthor=UCB, Inc.|ingredients=acrivastine[acrivastine];pseudoephedrine hydrochloride[pseudoephedrine]|pillImprint=404;SEMPREX-D|dosageValue=8|dosageUnit=mg|pillColor=Green;White|pillShape=Capsule|pillSize=16|pillScore=1}}


==References==
==References==
<references/>
{{reflist|2}}


{{Antihistamines}}
{{Antihistamines}}
{{Histaminergics}}


[[Category:H1 receptor antagonists]]
[[Category:H1 receptor antagonists]]
[[Category:Pharmacology stubs]]
[[Category:Pyridines]]
 
[[Category:Pyrrolidines]]
[[da:Acrivastin]]
[[Category:Alkenes]]
[[sk:Acrivastin]]
[[Category:Drug]]
 
{{WH}}
 
{{WS}}

Latest revision as of 02:40, 4 August 2015

{{Drugbox

| Verifiedfields = changed | verifiedrevid = 477241254 | IUPAC_name = (E)-3-{6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-yl-
prop-1-enyl]pyridin-2-yl}prop-2-enoic acid | image =Acrivastine.png

| tradename = | Drugs.com = International Drug Names | MedlinePlus = a682619 | pregnancy_AU = | pregnancy_US = B | legal_AU = | legal_CA = | legal_UK = | legal_US = Rx-only | routes_of_administration = oral

| elimination_half-life = 1.5 hours | excretion = Renal

| CAS_number_Ref =  ☒N | CAS_number = 87848-99-5 | ATC_prefix = R06 | ATC_suffix = AX18 | PubChem = 5284514 | DrugBank_Ref =  ☑Y | ChemSpiderID_Ref =  ☑Y | ChemSpiderID = 4447574 | UNII_Ref =  ☑Y | UNII = A20F9XAI7W | KEGG_Ref =  ☑Y | KEGG = D02760 | ChEMBL_Ref =  ☑Y | ChEMBL = 1224 | ChEBI_Ref =  ☒N | ChEBI = 83168

| C=22 | H=24 | N=2 | O=2 | molecular_weight = 348.438 g/mol | smiles = O=C(O)\C=C\c3nc(\C(=C\CN1CCCC1)c2ccc(cc2)C)ccc3 | InChI = 1/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+ | InChIKey = PWACSDKDOHSSQD-IUTFFREVBW | StdInChI_Ref =  ☑Y | StdInChI = 1S/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+ | StdInChIKey_Ref =  ☑Y | StdInChIKey = PWACSDKDOHSSQD-IUTFFREVSA-N }}

WikiDoc Resources for Acrivastine

Articles

Most recent articles on Acrivastine

Most cited articles on Acrivastine

Review articles on Acrivastine

Articles on Acrivastine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Acrivastine

Images of Acrivastine

Photos of Acrivastine

Podcasts & MP3s on Acrivastine

Videos on Acrivastine

Evidence Based Medicine

Cochrane Collaboration on Acrivastine

Bandolier on Acrivastine

TRIP on Acrivastine

Clinical Trials

Ongoing Trials on Acrivastine at Clinical Trials.gov

Trial results on Acrivastine

Clinical Trials on Acrivastine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Acrivastine

NICE Guidance on Acrivastine

NHS PRODIGY Guidance

FDA on Acrivastine

CDC on Acrivastine

Books

Books on Acrivastine

News

Acrivastine in the news

Be alerted to news on Acrivastine

News trends on Acrivastine

Commentary

Blogs on Acrivastine

Definitions

Definitions of Acrivastine

Patient Resources / Community

Patient resources on Acrivastine

Discussion groups on Acrivastine

Patient Handouts on Acrivastine

Directions to Hospitals Treating Acrivastine

Risk calculators and risk factors for Acrivastine

Healthcare Provider Resources

Symptoms of Acrivastine

Causes & Risk Factors for Acrivastine

Diagnostic studies for Acrivastine

Treatment of Acrivastine

Continuing Medical Education (CME)

CME Programs on Acrivastine

International

Acrivastine en Espanol

Acrivastine en Francais

Business

Acrivastine in the Marketplace

Patents on Acrivastine

Experimental / Informatics

List of terms related to Acrivastine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Acrivastine is a medication used for the treatment of allergies and hay fever. It is a second-generation H1-receptor antagonist antihistamine (like its base molecule triprolidine) and works by blocking Histamine H1 receptors.

This non-sedating[verification needed] antihistamine is sold under the brand name Benadryl Allergy Relief in the United Kingdom by McNeil Laboratories, not to be confused with Benadryl Once a Day, which is cetirizine and is also sold by McNeil in the UK. It is available as an over-the-counter medication in the UK, also offered with pseudoephedrine under the Benadryl brand

In the U.S., acrivastine is the active ingredient in the Semprex brand. Semprex-D is also acrivastine-based, but contains a decongestant, pseudoephedrine. Semprex-D is marketed in the U.S. by Actient Pharmaceuticals.[1]

Comparisons with other popular antihistamines

Unlike cetirizine or loratadine, the standard dosage of which is one tablet every day, a single acrivastine tablet may be taken up to three times a day.[2] Not to be taken by over 65's, pregnant women or people with compromised liver or kidney function.

Pill Images

{{#ask: Page Name::Acrivastine |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }} {{#subobject: 

 |Page Name=Acrivastine
 |Pill Name=SEMPREX_NDC_522440404.jpg
 |Drug Name=SEMPREX
 |Pill Ingred=ACRIVASTINE[ACRIVASTINE];PSEUDOEPHEDRINE HYDROCHLORIDE[PSEUDOEPHEDRINE]|+sep=;
 |Pill Imprint=404;SEMPREX;D
 |Pill Dosage=8 mg
 |Pill Color=Green|+sep=;
 |Pill Shape=Capsule
 |Pill Size (mm)=16
 |Pill Scoring=1
 |Pill Image=
 |Drug Author=Actient Pharmaceuticals, LLC
 |NDC=522440404

}}

{{#subobject: 

 |Page Name=Acrivastine
 |Pill Name=Semprex-D_NDC_530140404.jpg
 |Drug Name=Semprex-D
 |Pill Ingred=acrivastine[acrivastine];pseudoephedrine hydrochloride[pseudoephedrine]|+sep=;
 |Pill Imprint=404;SEMPREX-D
 |Pill Dosage=8 mg
 |Pill Color=Green;White|+sep=;
 |Pill Shape=Capsule
 |Pill Size (mm)=16
 |Pill Scoring=1
 |Pill Image=
 |Drug Author=UCB, Inc.
 |NDC=530140404

}}


References

  1. ↑ SEMPREX-D - acrivastine and pseudoephedrine hydrochloride capsule U.S. National Library of Medicine, National Institutes of Health, May 2008
  2. ↑ "Benadryl Allergy Relief". electronic Medicines Compendium (eMC). 2014. Retrieved 4 July 2014.
Retrieved from "https://www.wikidoc.org/index.php?title=Acrivastine&oldid=1126651"